The new benefits, which went into effect today, cover full and part-time US employees and allow for a “wide range of family care leave needs,” the Fridley, Minn.-based company said. These include time spent with a new child, caring for sick family members or caring for family after a spouse, child or parent is called to active military duty.
“These expanded benefits support our employees and their families in various life stages and make it possible for employees to dedicate their full attention to the people who matter most when needed,” chair & CEO Omar Ishrak said in a prepared statement.
The policy will allow up to six weeks away from work, and comes in addition to maternity benefits for birth mothers. With the addition, when combined with accrued paid time off, a new mother could take leave of up to 18 weeks paid at 100% for the duration, Medtronic said.
The company had previously offered five to seven weeks of paid leave for birth parents and one week for non-birth parents, and four weeks for compassionate leave to care for a terminally ill family member.
“We listened closely to what our employees were saying, and the needs they described. We believe we have created a benefit that goes well beyond current practice in the U.S. and affords Medtronic employees the valuable time they need with their families at critical times in their lives,” chief human resource officer Carol Surface said in a press release.
Medtronic said that currently the policy applies only to regular US employees, but that it is evaluating country-specific employment laws and regulations to “determine opportunities for additional policy changes to apply outside the United States.”
Becton Dickinson (NYSE:BDX) last week announced three new segment president appointments, tapping Alberto Mas to head its medical segment, Patrick Kaltenbach as prez of its life sciences segment and Bill Tozzi as its interventional segment interim prez.
Mas’ appointment will take effect May 29, the Franklin Lakes, N.J.-based company said. Mas will leave behind his previous position as life sciences segment head, which Kaltenbach will take over on May 29. Mas has previously served as prez of diagnostic systems, biosciences and medical surgical systems.
“Alberto is a proven leader who has excelled at every position he’s held at BD. He is the right leader for our largest segment, and I have full confidence he will continue to drive our growth and innovation strategy across the medical segment,” BD prez Tom Polen said in a prepared statement.
Kaltenbach is being lifted to life sciences head from his previously position as Agilent senior VP and life sciences and applied markets group prez, which he held since 2014.
“Attracting an industry leader of Patrick’s caliber to BD is a testament to our life sciences strategy and the segment’s progress toward becoming a transformative partner from discovery to diagnosis. Patrick brings a unique combination of deep experience and knowledge within the life sciences industry and a passion for creating value through innovation and technology. We are pleased to have his leadership as we continue to advance our life sciences Segment,” Polen said in a prepared release.
Tozzi previosly served as integration leader for its acquisition of C.R. Bard (NYSE:BCR), which closed last December. Prior to acting as integration leader, Tozzi acted as medication and procedural solutions prez for six years. Tozzi will replace John Groetelaars who is leaving the interventional segment prez position for an executive position at another company.
“Bill is a seasoned BD executive with a strong track record of success and deep integration experience. Together with the strong interventional segment leadership team driving the business, I am confident we are well positioned to fulfill our potential as a combined company. I would also like to thank John for his dedication and leadership to Bard and BD. I know that everyone at BD wishes him much success in the next chapter of his career,” Polen said in a press release.
Minnetronix said today it named Elissa Lindsoe as its new chief financial officer.
Prior to joining the St. Paul, Minn.-based company, Lindsoe served as SFO of Minnesota-based global manufacturing company Mocon, where she aided the company in its sale to Ametek. Lindsoe served as an independent consultant supporting the transition after the sale, Minnetronix said.
“We look forward to welcoming Elissa to the Minnetronix team at such an important and dynamic time in our company’s history. She is a proven and accomplished leader who will play an instrumental role in providing financial vision, strategy and leadership as we expand and grow our position in the market,” prez Jeremy Maniak said in a press release.
“Minnetronix is a unique company with an equally unique opportunity to accelerate its impact on the medical device market. I am looking forward to being part of a company with such a bright future and a compelling mission,” Lindsoe said in a prepared statement.
Zeus Industrial Products said today it named Steve Peterson as its new president.
Prior to moving to the president position, Peterson operated as global head of marketing and sales and senior VP, the Orangeburg, S.C.-based company said. Peterson will report directly to CEO John Winarchick.
In the position, Oswell will be responsible for product pipeline acceleration, including 3D surgical solutions and the company’s transcatheter aortic valve replacement project.
Prior to joining Admedus, Oswell held leadership roles with Boston Scientific (NYSE:BSX) and its Guidant subsidiary, as well as Medtronic. His most recent position was as senior program manager at Medtronic’s cardiac rhythm and heart failure operations.
“Michael has a strong track record as a results-driven leader in the medtech environment. He will be an excellent addition to the Admedus leadership team and his technical skill and experience will be an enormous advantage as we look to progress our range of new products in our development pipeline. His background in product development for some of the leading companies in the medtech industry will bring invaluable new perspective to our portfolio of development projects,” CEO Wayne Paterson said in a press release.